Part 2 (extension): Long-term evaluation of corticosteroid-releasing formulations to suppress implant device- related foreign body reactions and fibrosis
Implanted medical devices have dramatically improved the lives of millions of patients worldwide. However, in many cases, the body’s immune system rejects these devices and encapsulates the implant in fibrous scar tissue. This reaction is most detrimental to sensors for continuous monitoring and treatment of chronic conditions such as diabetes and those of the central nervous system. Device functionality is usually severely limited and risky additional surgeries for implant removal and reinsertion are required. Local delivery of corticosteroid drugs such as dexamethasone have been shown to suppress the immune response and extend device life. Nevertheless, restrictions on device size and requirements for extended drug presence (up to 1 month) have limited corticosteroid utility to date. The objective of the proposed project is to develop novel corticosteroid releasing technologies that can be processed in forms suitable for sensor applications, in particular for those used in continuous glucose monitors.